D-3608 Dovitinib, Free Base, >99%

Synonyms : [CHIR-258] [TKI-258]

Prices_reduced
  • Size
  • US $
  • £
  • ¥
  • 10 mg
  • 73
  • 68
  • 58
  • 11,300
  • Add to Cart Qty:
  • In stock
  • 25 mg
  • 144
  • 135
  • 116
  • 22,300
  • Add to Cart Qty:
  • In stock
  • 50 mg
  • 213
  • 199
  • 172
  • 32,900
  • Add to Cart Qty:
  • In stock
  • 100 mg
  • 356
  • 333
  • 287
  • 55,100
  • Add to Cart Qty:
  • In stock
  • 200 mg
  • 632
  • 592
  • 510
  • 97,700
  • Add to Cart Qty:
  • In stock
  • 500 mg
  • 1,080
  • 1,013
  • 872
  • 167,000
  • Add to Cart Qty:
  • In stock
  • 1 g
  • 1,770
  • 1,660
  • 1,430
  • 273,700
  • Add to Cart Qty:
  • In stock

Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.

To receive a Formal Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities Free Shipping and Handling to the U.S. and 32 Other Countries
  • M.W. 392.43
  • C21H21FN6O
  • [405169-16-6]

Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO. Disposal: A.

Select Lot Number to view Certificate of Analysis

View the SDS for this product

  • This research compound is the free base form of dovitinib.  We also offer the lactate salt form of dovitinib:  Cat. No. D-3699, Dovitinib, Lactate Salt.
  • This dovitinib product is the free base whose CAS number is given above.  The CAS number of the lactate salt form is 692737-80-7
  • Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use.
  • This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
  • Not available in some countries; not available to some institutions; not available for some uses.
92